Journal
ACS NANO
Volume 16, Issue 4, Pages 5246-5257Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.1c07237
Keywords
gender medicine; gold nanoparticles; liposome; mRNA LNP; fertility; ovarian cancer; breast cancer
Categories
Funding
- European Union's Horizon 2020 research and innovation program [680242-ERC]
- Phospholipid Research Center grant [ASC-2018-062/1-1]
- Israel Science Foundation [1881/21, 1778/13, 1421/17]
- Israel Ministry of Science Technology [3-16963, 3-17418]
- Ministry of Agriculture & Rural Development, Office of the Chief Scientist [323/19]
- Israel Innovation Authority for a Nofar grant [67967, 880326]
- Israel Ministry of Economy for a Kamin grant [69230, 63379]
- Israel Cancer Association [2015-0116]
- German-Israeli Foundation for Scientific Research and Development for a GIF Young grant [I-2328-1139.10/2012]
- European Union [908049]
- Louis Family Cancer Research Fund
- Leventhal 2020 COVID19 Research Fund (ATS) [11947]
- Mallat Family Foundation
- Unger Family Fund
- Carrie Rosenblatt Foundation for Cancer Research
- Taub Fellowship
- Technion Integrated Cancer Center (TICC)
- Russell Berrie Nanotechnology Institute
- Lorry I. Lokey Interdisciplinary Center for Life Sciences Engineering
- Israeli Ministry of Science and Technology
- Miriam and Aaron Gutwirth Memorial Fellowship
- Alon Fellowship
- TEVA Pharmaceuticals-NFBI-The National Forum for BioInnovators
- Technion Integrated Cancer Center (TICC) Rubinstein scholarship
- CRUK Multidisciplinary Project Award [C48390/A21153]
- EPSRC [EP/S032789/1]
- Wellcome EPSRC Centre for Medical Engineering at King's College London [WT 203148/Z/16/Z]
- Wellcome Trust Multiuser Equipment Grant [212885/Z/18/Z]
- National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and KCL [IS-BRC-1215-20006]
- European Research Council (ERC) [680242] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Physiological changes in the female menstrual cycle impact the biodistribution of nanoparticles in the reproductive system, which has significant implications for treatment.
Throughout the female menstrual cycle, physiological changes occur that affect the biodistribution of nanoparticles within the reproductive system. We demonstrate a 2-fold increase in nanoparticle accumulation in murine ovaries and uterus during ovulation, compared to the nonovulatory stage, following intravenous administration. This biodistribution pattern had positive or negative effects when drug-loaded nanoparticles, sized 100 nm or smaller, were used to treat different cancers. For example, treating ovarian cancer with nanomedicines during mouse ovulation resulted in higher drug accumulation in the ovaries, improving therapeutic efficacy. Conversely, treating breast cancer during ovulation, led to reduced therapeutic efficacy, due to enhanced nanoparticle accumulation in the reproductive system rather than at the tumor site. Moreover, chemotherapeutic nanoparticles administered during ovulation increased ovarian toxicity and decreased fertility compared to the free drug. The menstrual cycle should be accounted for when designing and implementing nanomedicines for females.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available